are operationally pandemic want financially Thank you, global COVID-XX Tim. challenges we responded include our long-term. how are by in the of both have result begin to to and this we how I discussion the for and a Accordingly, dynamic. recognizing the want impact I as for and thank today, positioned, us. Good collectively the and afternoon, that joining worldwide of you experiencing we
our unprecedented are We time circumstances day. by history are that indeed facing with an day evolving in
unique that us place our challenging a known uncertain, confidence It’s time. While chain supply for team enable little our in and will and balance vascular diagnostic is sheet, full impact of Surmodics manage in to through supply devices COVID-XX chain healthy occupies dedicated the the this reagents.
of thousands devices and every acute in Our day products both diagnostics test vascular and in used are elective expensively procedures.
an continue health and treatment As both to we the supply of ensure production to have for patients safety need, extensive and technologies undertaken of measures our the enabling essential in and team. diagnosis of
implemented have preparedness actually VP our did He was one. to Resources. we plan. Joe pandemic have have Stich We appointed of Yes, plan. Human IVD that Senior our and I according
As ensure decision-making. our speed Chief Officer executive of the leadership intent to Pandemic with and the necessary
operations customer team, and Beginning on-site and with involved in working employees our both been support, essential our has our manufacturing including U.S. services, in facilities. Irish
implemented measures have protocols COVID-XX. to including our We risk distancing to of safety the social staggered of team, exposure decrease ensure shifts and to on-site the
Medical elective degree depend guidance. are significant coming the more these to decision and to multitude The quarters. difficult Medical extent negatively of be Device business QX late business, our of is in and the our beginning COVID-XX forecast, impacted resulted Within in in suspend factors which procedures that being on in to our has a resulting the delay expected Device continue to of duration impacts
it on position not Notably, to steps results preserving quarter growth to our response be this IVD blush Tim taken liquidity our first operating to XX% objectives impacted execute and our strategic us while manage value for long-term in continuing in COVID-XX, have negatively QX. and to discuss detail. In greater experienced environment, our COVID-XX. with second we creation. to quite expenses did appear business will a pleased And I’m in by leave to to
We’re in and fortunate position with revenue financially solid on performance. to our a be focus optimizing continuous cash
Surmodics had and quite in pleased new distribute which products, new Surmodics commercialization will Cook that Cook to solutions platforms. whole-product relationship many We’ve proud our agreement products catheter. announce Medical technology our and with as use their far – are hydrophilic innovative where of they Cook, excellent platform with I’m medical long-standing .XXX” our PTA namely vascular modification two As strategy, a and balloon an surface .XXX”
partnership platforms. launch expand in .XXX” These used We’re from and these on which with ischemia. can later limb will balloon to patients catheters, .XXX” who this balloon new the XXXX, critical in help below-the-knee are excited suffering to be U.S.
We Cook. have product orders for to already shipped this the initial
objectives and remain and thrombectomy DCB Moving radial on to to We track the our programs, time our product with line. access. treatment for strategic pipeline platforms: and vascular the respect three
reviewing First, application. notified DCB. our that is am I CE latter to SurVeil discuss the our of pleased note let’s the stages Mark body in
to early the too of the in strength still the and we it’s remain the on application. process, of review outcome comment While data highly confident our
as we follow-up goals, far trial XX-month trial. patients the to visits for in SurVeil continue the conduct TRANSCEND As TRANSCEND with pivotal
have with the the result direct of some and respect We observed window site follow-up on the to delays a as depending location impact. COVID-XX
and/or missing limitations on data. current this the are on and management clearly this FDA very treat released the We document best engaging on-time of guidance topic. with The out-of-window a how FDA this during pandemic delayed including understands follow-up to trial recently
both data Symposium charing study We Holden Auckland, the planned New last Andrew in first-in-human week. from presentation a report. and completed working of SurVeil the trial Professors drug-coated planned window data and London safety these the to collection balloon. release we follow-up. late-breaking primary Zealand; to and to had of coordinators remain endpoint amount our a Australia, a With finalizing Barco Professor are our the cross the research with from in in at have We we we by expect site confident clinical in of data last respect well-known maximize Nonetheless, study to individually efficacy week and Remon to AVess, have as the investigators Sydney, demonstrate clinical
like the all to due symposium was canceled Unfortunately, this of others type COVID-XX.
late-breaking forum for We trial the present important data. are looking these appropriate to
and of that data Now quite directional I results. say is device important I provided AVess was encouraging. acutely you’re regarding provided the this in on time efficacy trial know that what It was can at And interested data the successful. safety the
while in small, were number freedom Now than months the XX the revascularization mind, from six subjects at of XX%. keep was greater subjects,
our results drug-coated six in deserves these of We clinical first-in-human are months. next but excited it AVess to the form within release trial balloon, detailed the
our on March. below-the-knee as we disease, initiate sirolimus Finally, Sundance balloon to Sundance poised trial early were the as for coated
and already ethics approvals received geographies. the of have We some and regulatory committee the relevant
end However, and quite due initiate study. to to safe of because least wonderful we work QX COVID-XX investigators the conditions presumed the had can at of we will trial, by sites with hope and but there delay. the to predict difficult contact, sequestering We be the to when the the it’s of favorable initiate to
controlled we artery can will with feasible. lesions. safely on FDA balloon radial initiate we our continue the progress knee below have .XXX” filed While treat radial the as early clearance the this and our We’ll trial and and disappointed, for what we radial have catheter. are make vasculature device as on This can to platform access
have to .XXX” balloon started We the work treat on via vessels radial proximal more access. catheter above behind knee and
pounds. the respect With
Our the data, the actual unique active responding submission FDA which the with we arterial agency to more requests an the for approval requires for device XXX(k) testing. from for clearance system, have thrombectomy and are
stay tuned. So
even on As as XXXX key as our objective fiscal COVID-XX you haven’t pandemic. see, can we – focused confront this we strategic
long ensure appropriately we as liquidity the remains that intact for investments have the for allocation strategic run. the programs pacing and maintaining we critically are and capital strategy we Our even
I’ll to Surmodics. So continue operate
realignment to Senior responsibilities had Teri of will our Officer in a Development last treated will company date had of Finally, a my early we Teri executive the this patients. improve April, President successfully XX role Office. resulting of leading has that held Chief Sides, launch ago, a years Product Marketing execution. Chief Marketing our become that market of have Vice multiple and products in millions
as XX issued an the is as member program XXth HR industry. pending and a of and He’s IVD and and position of add Surmodics’ coated well excellent team for culturally Senior Ireland. our President HR. the several supported HR Vice years Joe has organization in of to She leading Stitch a both build amazingly by plus patents HR experience given U.S. as continue culture. even drug was the his Joe choice we terrific founding organization a an leadership to will in in balloon our decades expired, with aligned and the responsibilities
me report agreements Vice Medical as Development been for a industry position Devices. in over almost Olson for to He’s agreement. at up Surmodics recent Senior for for President Charlie XX including years. directly XX XXX his and held of commercial Commercial responsible has over Charlie the will Cook and years signing to
focus Greaney, Chief partnership products to our scale this Officer of to agreements cost a component environment. up Operating which efficient is And our quite will these high-quality up our strategy, to be essential on able a Tom in finally, free
that both efforts in a of this of combination that with medical in XX capable and Nusrath most years the continue given area. simply decades And lead devices. is as to executive lead Affairs with Sultana is experience peripheral clinical over Clinical all this experience of his also will effort to products VP Tom drug
thank proud through also are you the effort lines I’m I our our us these providers, thank each of to healthcare all and all for want for patients. each on the times. team all day. contributions I and their front who to customers Surmodics’ want for unwavering supporting team – challenging to
We’re in dedication help deeply grateful us service pandemic. and this overcoming for their to
to fiscal our including our second the perspective some to with details results details to an liquidity over in Tim? is and impact now further turn our in COVID-XX position. the having company pandemic Tim I’ll of call more of provide fall XXXX financials
